Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1964472 | 0.98 | AOC1 (0.49) | AOC1AOC3KDM4CGAASLC22A12 | |
| SCHEMBL883732 | 0.84 | SLC22A12 (0.44) | AOC1AOC3KDM4CGAASLC22A12 | |
| SCHEMBL10202589 | 0.81 | LATS1 (0.46) | KDM4CGAASLC22A12MAPTGSK3A | |
| SCHEMBL3280218 | 0.80 | ALDH1A1 (0.52) | AOC1AOC3GAASLC22A12MAPT | |
| SCHEMBL11900964 | 0.80 | GAA (0.46) | GAASLC22A12MAPTGSK3AGSK3B | |
| SCHEMBL10264132 | 0.79 | AOC1 (0.51) | AOC1AOC3KDM4CGAASLC22A12 | |
| SCHEMBL26624210 | 0.77 | GAA (0.57) | KDM4CGAASLC22A12MAPTGSK3A | |
| SCHEMBL11900949 | 0.76 | GAA (0.43) | AOC1AOC3GAASLC22A12MAPT | |
| SCHEMBL4754435 | 0.73 | AOC1 (0.57) | AOC1AOC3KDM4CMAPTKDM4E | |
| SCHEMBL30448578 | 0.73 | AOC1 (0.57) | AOC1AOC3KDM4CMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| CN-103864754-B | Five-membered azole heterocycle compound and preparation method thereof, pharmaceutical composition and purposes | 中国科学院上海药物研究所 | 2016-12-21 | — | — | CN | disclosed |
| CN-106170290-A | Substituted di-amino-pyrimidine based compound, combinations thereof and treatment method thereof | 西格诺药品有限公司 | 2016-11-30 | — | — | CN | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| CN-104098587-A | 2, 4-diamino-thieno [2, 3-d] pyrimidine derivative as well as preparation method and application thereof | UNIV CAPITAL NORMAL | 2014-10-15 | — | — | CN | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8703759-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| CN-101355879-B | Chemical compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2012-10-17 | — | — | CN | disclosed |
| WO-2012003392-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| CN-101355879-A | Chemical compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | AOC1 3218/4885AOC3 3177/4885KDM4C 1892/4885 |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | AOC1 2551/4885AOC3 1298/4885KDM4C 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.